



Correction to: Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups

En-Hong Zhuo¹ · Wei-Jing Zhang² · Hao-Jiang Li² · Guo-Yi Zhang³ · Bing-Zhong Jing² · Jian Zhou² · Chun-Yan Cui² · Ming-Yuan Chen² · Ying Sun² · Li-Zhi Liu² · Hong-Min Cai^{1,4}

Published online: 26 April 2019
© European Society of Radiology 2019

Correction to: European Radiology <https://doi.org/10.1007/s00330-019-06075-1>

The original version of this article, published on 14 March 2019, unfortunately contained a mistake. The following correction has therefore been made in the original: There was a mistake in Table 1. The corrected table is given below.

The online version of the original article can be found at <https://doi.org/10.1007/s00330-019-06075-1>

✉ Li-Zhi Liu
liulizh@sysucc.org.com

✉ Hong-Min Cai
hmcai@scut.edu.cn

- ¹ School of Computer Science and Engineering, South China University of Technology, Guangzhou 510006, Guangdong Province, People's Republic of China
- ² State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou, Guangdong Province, People's Republic of China
- ³ Department of Radiation Oncology, Cancer Center, First People's Hospital of Foshan, Foshan 528000, Guangdong Province, People's Republic of China
- ⁴ Guangdong Provincial Key Lab of Computational Intelligence and Cyberspace Information, South China University of Technology, Guangzhou, People's Republic of China

Table 1 Demographic and clinical characteristics of patients in training and validation cohorts

Variable	Training cohort (<i>N</i> = 424) No. (%) of patients	Validation cohort (<i>N</i> = 234)
Age (years)		
Mean (SD)	45.3 (11.7)	44.4 (10.3)
Median (IQR)	45 (38–53)	44 (37.3–50)
Sex		
Male	315 (74.3)	167 (71.4)
Female	109 (25.7)	67 (28.6)
T category		
T1	93 (21.9)	79 (33.8)
T2	59 (13.9)	25 (10.7)
T3	162 (38.2)	74 (31.6)
T4	110 (25.9)	56 (23.9)
N category		
N0	104 (24.5)	54 (23.1)
N1	256 (60.4)	150 (64.1)
N2	59 (13.9)	23 (9.8)
N3	5 (1.2)	7 (3.0)
Overall stage		
I	37 (8.7)	29 (12.4)
II	91 (21.5)	67 (28.6)
III	182 (42.9)	76 (32.5)
IV-a	114 (26.9)	62 (26.5)
Follow-up time		
Median (IQR)	63.0 (56.1–67.1)	62.9 (57.1–66.3)

SD standard deviation, *IQR* interquartile range

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.